modelMethotrexate_1
Extends from Pharmacolibrary.Drugs.ATC.L.L04AX03_1.
Information
| name: | Methotrexate_1 | |
| ATC code: | L04AX03_1 | route: | oral |
| compartments: | 1 | |
| dosage: | 15 | mg |
| volume of distribution: | 12.5 | L |
| clearance: | 7.48 | L/h |
| other parameters in model implementation | ||
Methotrexate is an antimetabolite and antifolate drug, widely used in the treatment of various cancers (e.g., leukemia, lymphoma, breast cancer) and autoimmune diseases such as rheumatoid arthritis and psoriasis. It inhibits dihydrofolate reductase, blocking DNA synthesis and cell replication. Methotrexate is approved and used in clinical practice today for both oncological and non-oncological indications.
Pharmacokinetics
Pharmacokinetic parameters after oral administration in adult patients with rheumatoid arthritis. Oral bioavailability varies.
References
Demase, K, et al., & Sparrow, MP (2023). The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD. Journal of clinical medicine 12(13) –. DOI:10.3390/jcm12134382 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37445417
Botson, JK, et al., & Weinblatt, ME (2023). A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. Arthritis & rheumatology (Hoboken, N.J.) 75(2) 293–304. DOI:10.1002/art.42335 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36099211
Godfrey, C, et al., & Kremer, J (1998). The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. British journal of clinical pharmacology 46(4) 369–376. DOI:10.1046/j.1365-2125.1998.t01-1-00790.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/9803986
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)